Cargando…
2788. Cefepime or Carbapenem Definitive Therapy Versus Other Antibiotics for Blood Stream Infections Caused by Non-ESBL-Producing Serratia Marcescens: A Multicenter Retrospective Cohort Study
BACKGROUND: Serratia Marcescens causes serious infections. Carbapenems were preferred due to fear of inducible AmpC resistance. IDSA guidance now recommends ceftriaxone, and in high-burden cases, cefepime. Evidence on Serratia bacteremia treatment is limited. This study compares outcomes of cefepime...
Autores principales: | Mughrabi, Abdallah, Maamari, Julian, Philips, Timothy, Alabbasi, Afaq, Brooks, Aislinn, Nuriev, Rinat, Zenkin, Lisa, Jaber, Bertrand, Nader, Claudia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677257/ http://dx.doi.org/10.1093/ofid/ofad500.2399 |
Ejemplares similares
-
2789. Cefepime Versus Non-Cefepime/Non-Carbapenem Therapy for Blood Stream Infections Caused by Non-ESBL-Producing Serratia Marcescens: A Subgroup Analysis of The Carbapenem-Serratia Multicenter Retrospective Cohort Study
por: Mughrabi, Abdallah, et al.
Publicado: (2023) -
2787. Carbapenem Versus Non-Carbapenem Based Therapy for Blood Stream Infection Caused by Serratia Marcescens: A Multicenter Retrospective Cohort Study
por: Mughrabi, Abdallah, et al.
Publicado: (2023) -
141. Evaluating Cefepime And Alternative Beta-lactams For The Treatment Of Serratia marcescens Blood Stream Infections
por: Vicente-Lopez, Natcha, et al.
Publicado: (2022) -
Etymologia: Serratia marcescens
por: Nazzaro, Gianluca
Publicado: (2019) -
Serratia marcescens Endocarditis
por: Elkattawy, Sherif, et al.
Publicado: (2021)